Trana Discovery assays identify compounds that work through a unique mechanism of action: inhibition of the target pathogen’s ability to use transfer RNA (tRNA) essential for propagation. The proprietary technology mimics the critical components of naturally occurring tRNA, allowing the synthetic compound to be used as research tools and components in drug discovery assays.
Radio in Vivo, hosted by science writer Ernie Hood, is a weekly one-hour interview program focusing on scientific developments in the North Carolina's Research Triangle Park and the surrounding Triangle scientific community. The program airs each Wednesday at 11:00 AM eastern time on WCOM-FM 103.5, Carrboro's community radio station and through the Internet at http://www.communityradio.coop/
The use of high-throughput screening assays developed by Trana Discovery can reduce the cost and time for drug discovery and provide licensing opportunities for exclusive rights to new drug classes. Trana recently perfected its high-throughput HIV drug discovery assay which is capable of identifying compounds that interfere with the use of tRNA by the human immunodeficiency virus (HIV), the cause of AIDS. An HTS assay for Staphylococcus aureus bacteria is currently under development. Organizations interested in licensing either assay should contact Trana at email@example.com or by calling 866-390-3452 (toll free) or +1-919-342-6192.
For more information, please visit http://www.tranadiscovery.com .
Karl von Gunten (919) 931-1434
# # #
Trana Discovery, an anti-infective drug discovery technology company, helps its partners find new classes of drugs for the treatment of serious bacterial, viral, and fungal infectious diseases. For more information, please visit www.tranadiscovery.com.